A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy
Epilepsy is one of the most common chronic neurological diseases, and its pharmacological treatment holds great importance for both physicians and national authorities, especially considering the high proportion of drug-resistant patients (about 30%). Lacosamide (LCM) is an effective and well-tolera...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-07-01
|
| Series: | Neurobiology of Disease |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996118300949 |
| _version_ | 1818827644751314944 |
|---|---|
| author | Gabriele Ruffolo Carlo Di Bonaventura Pierangelo Cifelli Cristina Roseti Jinane Fattouch Alessandra Morano Cristina Limatola Eleonora Aronica Eleonora Palma Anna Teresa Giallonardo |
| author_facet | Gabriele Ruffolo Carlo Di Bonaventura Pierangelo Cifelli Cristina Roseti Jinane Fattouch Alessandra Morano Cristina Limatola Eleonora Aronica Eleonora Palma Anna Teresa Giallonardo |
| author_sort | Gabriele Ruffolo |
| collection | DOAJ |
| description | Epilepsy is one of the most common chronic neurological diseases, and its pharmacological treatment holds great importance for both physicians and national authorities, especially considering the high proportion of drug-resistant patients (about 30%). Lacosamide (LCM) is an effective and well-tolerated new-generation antiepileptic drug (AED), currently licensed as add-on therapy for partial-onset seizures. However, LCM mechanism of action is still a matter of debate, although its effect on the voltage sensitive sodium channels is by far the most recognized.This study aimed to retrospectively analyze a cohort of 157 drug-resistant patients treated with LCM to describe the most common and effective therapeutic combinations and to investigate if the LCM can affect also GABAA-mediated neurotransmission as previously shown for levetiracetam (LEV).In our cohort, LEV resulted the compound most frequently associated with LCM in the responder subgroup. We therefore translated this clinical observation into the laboratory bench by taking advantage of the technique of “membrane micro-transplantation” in Xenopus oocytes and electrophysiological approaches to study human GABAA-evoked currents.In cortical brain tissues from refractory epileptic patients, we found that LCM reduces the use-dependent GABA impairment (i.e., “rundown”) that it is considered one of the specific hallmarks of drug-resistant epilepsies.Notably, in line with our clinical observations, we found that the co-treatment with subthreshold concentrations of LCM and LEV, which had no effect on GABAA currents on their own, reduced GABA impairment in drug-resistant epileptic patients, and this effect was blocked by PKC inhibitors.Our findings demonstrate, for the first time, that LCM targets GABAA receptors and that it can act synergistically with LEV, improving the GABAergic function. This novel mechanism might contribute to explain the clinical efficacy of LCM-LEV combination in several refractory epileptic patients. |
| first_indexed | 2024-12-19T00:46:50Z |
| format | Article |
| id | doaj.art-e1781f9e58f54cd1bec601562529ddc5 |
| institution | Directory Open Access Journal |
| issn | 1095-953X |
| language | English |
| last_indexed | 2024-12-19T00:46:50Z |
| publishDate | 2018-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neurobiology of Disease |
| spelling | doaj.art-e1781f9e58f54cd1bec601562529ddc52022-12-21T20:44:15ZengElsevierNeurobiology of Disease1095-953X2018-07-011155968A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsyGabriele Ruffolo0Carlo Di Bonaventura1Pierangelo Cifelli2Cristina Roseti3Jinane Fattouch4Alessandra Morano5Cristina Limatola6Eleonora Aronica7Eleonora Palma8Anna Teresa Giallonardo9Department of Physiology and Pharmacology, Laboratory Affiliated to Istituto Pasteur-Italia, University of Rome Sapienza, Rome, ItalyDepartment of Neurology and Psychiatry, University of Rome Sapienza, Rome, ItalyIRCCS Neuromed, Pozzilli (IS), ItalyIRCCS San Raffaele Pisana, Rome, ItalyDepartment of Neurology and Psychiatry, University of Rome Sapienza, Rome, ItalyDepartment of Neurology and Psychiatry, University of Rome Sapienza, Rome, ItalyDepartment of Physiology and Pharmacology, Laboratory Affiliated to Istituto Pasteur-Italia, University of Rome Sapienza, Rome, Italy; IRCCS Neuromed, Pozzilli (IS), ItalyUniversity of Amsterdam, Amsterdam, The Netherlands; Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Amsterdam, The Netherlands; Stichting Epilepsie Instellingen Nederland (SEIN), The NetherlandsDepartment of Physiology and Pharmacology, Laboratory Affiliated to Istituto Pasteur-Italia, University of Rome Sapienza, Rome, Italy; IRCCS San Raffaele Pisana, Rome, Italy; Corresponding author at: Department of Physiology and Pharmacology, P.le A. Moro 5, 00185 Roma, Italy.Department of Neurology and Psychiatry, University of Rome Sapienza, Rome, ItalyEpilepsy is one of the most common chronic neurological diseases, and its pharmacological treatment holds great importance for both physicians and national authorities, especially considering the high proportion of drug-resistant patients (about 30%). Lacosamide (LCM) is an effective and well-tolerated new-generation antiepileptic drug (AED), currently licensed as add-on therapy for partial-onset seizures. However, LCM mechanism of action is still a matter of debate, although its effect on the voltage sensitive sodium channels is by far the most recognized.This study aimed to retrospectively analyze a cohort of 157 drug-resistant patients treated with LCM to describe the most common and effective therapeutic combinations and to investigate if the LCM can affect also GABAA-mediated neurotransmission as previously shown for levetiracetam (LEV).In our cohort, LEV resulted the compound most frequently associated with LCM in the responder subgroup. We therefore translated this clinical observation into the laboratory bench by taking advantage of the technique of “membrane micro-transplantation” in Xenopus oocytes and electrophysiological approaches to study human GABAA-evoked currents.In cortical brain tissues from refractory epileptic patients, we found that LCM reduces the use-dependent GABA impairment (i.e., “rundown”) that it is considered one of the specific hallmarks of drug-resistant epilepsies.Notably, in line with our clinical observations, we found that the co-treatment with subthreshold concentrations of LCM and LEV, which had no effect on GABAA currents on their own, reduced GABA impairment in drug-resistant epileptic patients, and this effect was blocked by PKC inhibitors.Our findings demonstrate, for the first time, that LCM targets GABAA receptors and that it can act synergistically with LEV, improving the GABAergic function. This novel mechanism might contribute to explain the clinical efficacy of LCM-LEV combination in several refractory epileptic patients.http://www.sciencedirect.com/science/article/pii/S0969996118300949EpilepsyGABAA receptorDrug-resistanceLacosamideLevetiracetamXenopus oocytes |
| spellingShingle | Gabriele Ruffolo Carlo Di Bonaventura Pierangelo Cifelli Cristina Roseti Jinane Fattouch Alessandra Morano Cristina Limatola Eleonora Aronica Eleonora Palma Anna Teresa Giallonardo A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy Neurobiology of Disease Epilepsy GABAA receptor Drug-resistance Lacosamide Levetiracetam Xenopus oocytes |
| title | A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy |
| title_full | A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy |
| title_fullStr | A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy |
| title_full_unstemmed | A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy |
| title_short | A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy |
| title_sort | novel action of lacosamide on gabaa currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy |
| topic | Epilepsy GABAA receptor Drug-resistance Lacosamide Levetiracetam Xenopus oocytes |
| url | http://www.sciencedirect.com/science/article/pii/S0969996118300949 |
| work_keys_str_mv | AT gabrieleruffolo anovelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT carlodibonaventura anovelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT pierangelocifelli anovelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT cristinaroseti anovelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT jinanefattouch anovelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT alessandramorano anovelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT cristinalimatola anovelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT eleonoraaronica anovelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT eleonorapalma anovelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT annateresagiallonardo anovelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT gabrieleruffolo novelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT carlodibonaventura novelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT pierangelocifelli novelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT cristinaroseti novelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT jinanefattouch novelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT alessandramorano novelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT cristinalimatola novelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT eleonoraaronica novelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT eleonorapalma novelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy AT annateresagiallonardo novelactionoflacosamideongabaacurrentssetsthegroundforasynergicinteractionwithlevetiracetamintreatmentofepilepsy |